Cover Image
市場調查報告書

ActogeniX NV:產品平台分析

ActogeniX NV - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224741
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
ActogeniX NV:產品平台分析 ActogeniX NV - Product Pipeline Review - 2015
出版日期: 2015年02月28日 內容資訊: 英文 35 Pages
簡介

本報告提供ActogeniX NV的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

ActogeniX NV的基本資料

ActogeniX NV概要

  • 主要資訊
  • 企業資料

ActogeniX NV:R&D概要

  • 主要的治療範圍

ActogeniX NV:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

ActogeniX NV:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

ActogeniX NV:藥物簡介

  • AG-013
  • AG-014
  • 面向過敏疾病細胞治療藥
  • 面向第二型糖尿病細胞治療藥
  • 適合麩質過敏症的基因重組細菌
  • 適合第一型糖尿病的基因重組細菌
  • 適合難辨梭狀芽孢桿菌腸疾病的基因重組細菌

ActogeniX NV:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

ActogeniX NV:最近的開發平台趨勢

ActogeniX NV:暫停中的計劃

ActogeniX NV:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06828CDB

Summary

Global Markets Direct's, 'ActogeniX NV - Product Pipeline Review - 2015', provides an overview of the ActogeniX NV's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ActogeniX NV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ActogeniX NV including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ActogeniX NV's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ActogeniX NV's pipeline products

Reasons to buy

  • Evaluate ActogeniX NV's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ActogeniX NV in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ActogeniX NV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ActogeniX NV and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ActogeniX NV
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ActogeniX NV and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ActogeniX NV Snapshot
    • ActogeniX NV Overview
    • Key Information
    • Key Facts
  • ActogeniX NV - Research and Development Overview
    • Key Therapeutic Areas
  • ActogeniX NV - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ActogeniX NV - Pipeline Products Glance
    • ActogeniX NV - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • ActogeniX NV - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ActogeniX NV - Drug Profiles
    • AG-013
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • certolizumab pegol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Genetically Engineered Bacteria Expressing IL-10 for IBD and Colon Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Genetically Engineered Bacteria for Allergic Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Genetically Engineered Bacteria for Celiac Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Genetically Engineered Bacteria for Type 1 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Genetically Engineered Bacteria for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Genetically Engineered Bacteria Expressing Antibody for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Genetically Engineered Bacteria for Clostridium Difficile Enteropathy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Genetically Engineered Bacteria for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ActogeniX NV - Pipeline Analysis
    • ActogeniX NV - Pipeline Products by Target
    • ActogeniX NV - Pipeline Products by Route of Administration
    • ActogeniX NV - Pipeline Products by Molecule Type
    • ActogeniX NV - Pipeline Products by Mechanism of Action
  • ActogeniX NV - Recent Pipeline Updates
  • ActogeniX NV - Dormant Projects
  • ActogeniX NV - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ActogeniX NV, Key Information
  • ActogeniX NV, Key Facts
  • ActogeniX NV - Pipeline by Indication, 2015
  • ActogeniX NV - Pipeline by Stage of Development, 2015
  • ActogeniX NV - Monotherapy Products in Pipeline, 2015
  • ActogeniX NV - Phase II, 2015
  • ActogeniX NV - Phase I, 2015
  • ActogeniX NV - Preclinical, 2015
  • ActogeniX NV - Discovery, 2015
  • ActogeniX NV - Pipeline by Target, 2015
  • ActogeniX NV - Pipeline by Route of Administration, 2015
  • ActogeniX NV - Pipeline by Molecule Type, 2015
  • ActogeniX NV - Pipeline Products by Mechanism of Action, 2015
  • ActogeniX NV - Recent Pipeline Updates, 2015
  • ActogeniX NV - Dormant Developmental Projects,2015

List of Figures

  • ActogeniX NV - Pipeline by Top 10 Indication, 2015
  • ActogeniX NV - Pipeline by Stage of Development, 2015
  • ActogeniX NV - Monotherapy Products in Pipeline, 2015
  • ActogeniX NV - Pipeline by Top 10 Target, 2015
  • ActogeniX NV - Pipeline by Top 10 Route of Administration, 2015
  • ActogeniX NV - Pipeline by Top 10 Molecule Type, 2015
  • ActogeniX NV - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top